Clinical responses to ERK inhibition in BRAF V600E -mutant colorectal cancer predicted using a compu...
Clinical responses to ERK inhibition in BRAF V600E -mutant colorectal cancer predicted using a computational model
About this item
Full title
Author / Creator
Publisher
England: Nature Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
England: Nature Publishing Group
Subjects
More information
Scope and Contents
Contents
Approximately 10% of colorectal cancers harbor
mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab...
Alternative Titles
Full title
Clinical responses to ERK inhibition in BRAF V600E -mutant colorectal cancer predicted using a computational model
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6bfc02d0615b4d33ac88a7be2e3e419b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6bfc02d0615b4d33ac88a7be2e3e419b
Other Identifiers
ISSN
2056-7189
E-ISSN
2056-7189
DOI
10.1038/s41540-017-0016-1
